(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...
The Targeted Pulse: New Trial Evaluating Iadademstat/Azacitidine in MDS and Positive Trends in HNSCC
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its ...
At the Huawei Product & Solution Launch during MWC Barcelona 2025, Cao Ming, Vice President of Huawei and President of Huawei ...
Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...
Sun Pharma will pay an upfront cash payment of $4.1 per share, which amounts to an aggregate consideration of $355 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback